Global Multicancer Screening Market Size is valued at USD 2.3 Bn in 2024 and is predicted to reach USD 9.7 Bn by the year 2034 at a 15.4% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
The increasing incidence of cancer and the requirement for early diagnosis diagnostics, which make simple disease management possible and thereby reduce the death rate, are the main drivers of market revenue growth. 2020 saw about 10 million cancer-related deaths worldwide, making it the leading cause of death. The most frequent cancers in terms of new cases in 2020 were breast, lung, colon and rectum, prostate, skin, and stomach.
Consequently, there is a peak in demand for MCEDS as cancer incidence rises. Multi-Cancer Early Detection (MCED) testing, a minimally invasive technology, can identify malignancies from many organ sites with just one test, reducing the number of operations and saving time.
Large-scale R&D for the creation of MCED is another element boosting market revenue growth. For instance, research to identify and validate novel biomarker combinations that detect various malignancies early was initiated in Singapore on July 8, 2022. For instance, the biotechnology business MIRXES Ptr Ltd. disclosed that Project CADENCE had started following the signing of a memorandum of agreement (Cancer Detected Early can be Cured). This project is the first large-scale clinical research project of its kind in the world, and it will enable the development of a multi-cancer early detection test for up to nine cancers with a high incidence and mortality rate, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
The Multicancer Screening market is segmented on the basis of test type, technology, sample, method, cancer type, application, and end-user. Test type segment includes Laboratory Developed Tests (LDTs) and In-Vitro Diagnostics (IVDs). The technology segment includes Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies. By sample, the market is segmented into Tissue, Blood, Saliva, Buccal Swabs, and Others.
The method segment includes DNA, RNA, and Proteins. By cancer type, the market is segmented as Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types. Application segment covers Clinical and Research. By end user, the market is categorized into Hospitals, Diagnostic and Clinical Laboratories, Academic and Research Institutions, and Other End Users
With the majority of market revenue, the hospitals segment dominated the entire market. The prevalence of specialized medical professionals and healthcare workers who are involved in diagnosis and treatment is responsible for this segment's dominance. Hospitals are used as a platform to inform and raise public knowledge of various illnesses and ailments. The target audience knows very little about MCED, a new technology. As a result, hospitals examine asymptomatic people for several types to facilitate therapy.
Due to the fact that it offers testing for several cancers, the LDT category had the highest revenue share. Gene panels target the identification of hereditary malignancies, and rising public awareness of hereditary diseases is expediting demand for genetic testing that can identify cancers early and enhance patient survival rates.
In Europe, the use of multi-cancer early detection has expanded in industries including hospitals, labs, diagnostic centers, and other significant market developments. The global market expansion in Europe is anticipated to be encouraged by the rising population, which is linked to a greater vulnerability to cancer-related chronic diseases and the economical diagnosis of chronic diseases in rural areas.
The market has grown significantly as a result of the increasing number of instances in Europe. For instance, according to a 2019 article by Eurostat, among the EU Member States, Hungary and Croatia had the highest standardized death rates for cancer, each with at least 300 per 100 000 residents. Due to these reasons, the European Union has started and intensified its attention on regional multi-cancer early detection programs.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 2.3 Bn |
| Revenue forecast in 2034 | USD 9.7 Bn |
| Growth rate CAGR | CAGR of 15.4% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Test Type, Technology, Sample, Method, Cancer Type, Application, And End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock DX, Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fulgent Genetics., Genecast Biotechnology Co., Ltd, Guardant Health, Inc., Illumina, Inc., Konica Minolta, Inc., Laboratory Corporation of America Holdings., Myriad Genetics, Inc., Tempus, and Thermo Fisher Scientific Inc. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Multicancer Screening Market By Test Type-
Multicancer Screening Market By Technology-
Multicancer Screening Market By Sample-
Multicancer Screening Market By Method -
Multicancer Screening Market By Cancer Type-
Multicancer Screening Market By Application -
Multicancer Screening Market By End User -
Multicancer Screening Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.